{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:29:38Z","timestamp":1793449778507,"version":"4.5.0"},"reference-count":32,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To estimate the incidence of herpes zoster (HZ) in patients with rheumatoid arthritis (RA) compared with the general population in the USA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective, longitudinal cohort study used data from an administrative claims database containing both commercial and Medicare Advantage Part D data, with a data period from October 2015 to February 2020. Patients were aged \u2265 18 years and divided into 2 cohorts: patients with RA and patients without RA. Diagnosis and procedure codes were used to identify HZ cases and calculate incidence rates (IRs) of HZ in the 2 cohorts. Data were stratified by age group (ie, 18-49, 18-29, 30-39, 40-49, 50-64, and \u2265 65 yrs) and RA therapy type. IR ratios (IRRs), adjusted by cohort baseline characteristics, were estimated using generalized linear models to compare the incidence of HZ between cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall IR of HZ was higher in the RA cohort (21.5 per 1000 person-years [PY]; N = 67,650) than in the non-RA cohort (7.6 per 1000 PY; N = 11,401,743). The highest IRs in both cohorts were observed in the age group of \u2265 65 yrs (23.4 and 11.4 per 1000 PY in the RA cohort and non-RA cohort, respectively). The overall adjusted IRR of HZ was 1.93 (95% CI 1.87-1.99,<jats:italic>P<\/jats:italic>&lt; 0.001) for the RA cohort compared with the non-RA cohort. In the RA cohort, the highest IRs by medication class were observed in patients using corticosteroids and those using Janus kinase inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results highlight the increased incidence of HZ in patients with RA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.220986","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T13:34:08Z","timestamp":1675258448000},"page":"873-880","source":"Crossref","is-referenced-by-count":27,"title":["Incidence of Herpes Zoster in Patients With Rheumatoid Arthritis in the United States: A Retrospective Cohort Study"],"prefix":"10.3899","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8008-8003","authenticated-orcid":false,"given":"David","family":"Singer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9047-3941","authenticated-orcid":false,"given":"Philippe","family":"Thompson-Leduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4735-057X","authenticated-orcid":false,"given":"Sara","family":"Poston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3695-3546","authenticated-orcid":false,"given":"Deepshekhar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8281-2496","authenticated-orcid":false,"given":"Wendy Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7269-2884","authenticated-orcid":false,"given":"Siyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9689-4659","authenticated-orcid":false,"given":"Francesca","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-6687","authenticated-orcid":false,"given":"Mei S.","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-8976","authenticated-orcid":false,"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"2023080910450957000_50.7.873.1","doi-asserted-by":"publisher","DOI":"10.4065\/84.3.274"},{"key":"2023080910450957000_50.7.873.2","first-page":"142","article-title":"Eye and periocular skin involvement in herpes zoster infection","volume":"4","author":"Kalogeropoulos","year":"2015","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"2023080910450957000_50.7.873.3","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-37"},{"key":"2023080910450957000_50.7.873.4","unstructured":"Centers for Disease Control and Prevention . Complications of shingles. [Internet. Accessed May 10, 2022.] Available from: https:\/\/www.cdc.gov\/shingles\/about\/complications.html."},{"key":"2023080910450957000_50.7.873.5","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-013-0550-8"},{"key":"2023080910450957000_50.7.873.6","doi-asserted-by":"publisher","DOI":"10.1177\/2051013615599151"},{"key":"2023080910450957000_50.7.873.7","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","article-title":"Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology"},{"key":"2023080910450957000_50.7.873.8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21928"},{"key":"2023080910450957000_50.7.873.9","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/jcm10061241","article-title":"Managing osteoporosis and joint damage in patients with rheumatoid arthritis: an overview","volume":"10","author":"Tanaka","year":"2021","journal-title":"J Clin Med"},{"key":"2023080910450957000_50.7.873.10","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"2023080910450957000_50.7.873.11","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1002\/art.39670","article-title":"Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023080910450957000_50.7.873.12","doi-asserted-by":"crossref","first-page":"e0226255","DOI":"10.1371\/journal.pone.0226255","article-title":"Inferring disease severity in rheumatoid arthritis using predictive modeling in administrative claims databases","volume":"14","author":"Chandran","year":"2019","journal-title":"PLoS One"},{"key":"2023080910450957000_50.7.873.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.075"},{"key":"2023080910450957000_50.7.873.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.20827"},{"key":"2023080910450957000_50.7.873.15","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13075-020-02310-z","article-title":"Use of ICD-10 diagnosis codes to identify seropositive and seronegative rheumatoid arthritis when lab results are not available","volume":"22","author":"Curtis","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2023080910450957000_50.7.873.16","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"2023080910450957000_50.7.873.17","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988."},{"key":"2023080910450957000_50.7.873.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.10.060"},{"key":"2023080910450957000_50.7.873.19","doi-asserted-by":"publisher","DOI":"10.4065\/82.11.1341"},{"key":"2023080910450957000_50.7.873.20","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.1016\/j.vaccine.2018.09.013","article-title":"Herpes zoster in the context of varicella vaccination \u2013 an equation with several variables","volume":"36","author":"Wutzler","year":"2018","journal-title":"Vaccine"},{"key":"2023080910450957000_50.7.873.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0150.x"},{"key":"2023080910450957000_50.7.873.22","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.mayocp.2021.05.029","article-title":"Corticosteroid use and risk of herpes zoster in a population-based cohort","volume":"96","author":"Qian","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2023080910450957000_50.7.873.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.3922"},{"key":"2023080910450957000_50.7.873.24","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001395"},{"key":"2023080910450957000_50.7.873.25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014032"},{"key":"2023080910450957000_50.7.873.26","doi-asserted-by":"crossref","first-page":"1759720X20936059","DOI":"10.1177\/1759720X20936059","article-title":"JAK inhibitors and infections risk: focus on herpes zoster","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2023080910450957000_50.7.873.27","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S2665-9913(21)00034-5","article-title":"Type I interferon, anti-interferon antibodies, and COVID-19","volume":"3","author":"Calabrese","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023080910450957000_50.7.873.28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/biof.6","article-title":"Interferons and viral infections","volume":"35","author":"Fensterl","year":"2009","journal-title":"Biofactors"},{"key":"2023080910450957000_50.7.873.29","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5021\/ad.2018.30.2.253","article-title":"Validation of herpes zoster diagnosis code in the electronic medical record: a retrospective, multicenter study","volume":"30","author":"Kim","year":"2018","journal-title":"Ann Dermatol"},{"key":"2023080910450957000_50.7.873.30","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0305"},{"key":"2023080910450957000_50.7.873.31","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7103a2"},{"key":"2023080910450957000_50.7.873.32","unstructured":"Centers for Disease Control and Prevention . Clinical considerations for use of recombinant zoster vaccine (RZV, Shingrix) in immunocompromised adults aged \u226519 years. [Internet. Accessed September 15, 2022.] Available from: https:\/\/www.cdc.gov\/shingles\/vaccination\/immunocompromised-adults.html"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.220986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T17:47:04Z","timestamp":1691603224000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,1]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.3899\/jrheum.220986"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.220986","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}